Cathay Biotech Inc (688065) - Total Liabilities
Based on the latest financial reports, Cathay Biotech Inc (688065) has total liabilities worth CN¥2.23 Billion CNY (≈ $326.05 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cathay Biotech Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Cathay Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. See Cathay Biotech Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Cathay Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Cathay Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LYFT Inc
NASDAQ:LYFT
|
USA | $5.86 Billion |
|
Fomento de Construcciones y Contratas SA
MC:FCC
|
Spain | €11.06 Billion |
|
InnoDisk
TWO:5289
|
Taiwan | NT$5.43 Billion |
|
Walsin Lihwa Corp
TW:1605
|
Taiwan | NT$121.80 Billion |
|
Sigma Foods, S.A.B. de C.V.
MX:SIGMAFA
|
Mexico | MX$108.05 Billion |
|
Warehouses de Pauw Comm VA
BR:WDP
|
Belgium | €4.05 Billion |
|
Etsy, Inc.
NASDAQ:ETSY
|
USA | $3.77 Billion |
|
Marathon Digital Holdings Inc
NASDAQ:MARA
|
USA | $2.62 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Cathay Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688065 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cathay Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cathay Biotech Inc (2016–2024)
The table below shows the annual total liabilities of Cathay Biotech Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.92 Billion ≈ $573.68 Million |
-3.44% |
| 2023-12-31 | CN¥4.06 Billion ≈ $594.14 Million |
+45.58% |
| 2022-12-31 | CN¥2.79 Billion ≈ $408.13 Million |
+84.61% |
| 2021-12-31 | CN¥1.51 Billion ≈ $221.07 Million |
+132.16% |
| 2020-12-31 | CN¥650.74 Million ≈ $95.22 Million |
-51.43% |
| 2019-12-31 | CN¥1.34 Billion ≈ $196.07 Million |
-20.38% |
| 2018-12-31 | CN¥1.68 Billion ≈ $246.26 Million |
+79.68% |
| 2017-12-31 | CN¥936.58 Million ≈ $137.05 Million |
+113.24% |
| 2016-12-31 | CN¥439.21 Million ≈ $64.27 Million |
-- |
About Cathay Biotech Inc
Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for … Read more